Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plasmacytoid dendritic cell vaccine (Radboud University Medical Center)
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranodal
01
Overview
This is an autologous dendritic cell-based cancer vaccine developed by Radboud University Medical Center for the treatment of stage III melanoma. The vaccine is composed of naturally occurring plasmacytoid dendritic cells (pDCs) isolated from the patient's peripheral blood. These cells are activated and loaded ex vivo with melanoma-associated peptide antigens, specifically gp100 and tyrosinase. Following preparation, the vaccine is administered via intranodal injection to stimulate the patient's immune system, specifically aiming to induce tumor-specific CD4+ and CD8+ T-cell responses. In clinical studies (such as NCT02574377), it has been evaluated both as a monotherapy and in combination with myeloid dendritic cells (cDC2s) to improve outcomes in patients with completely resected stage III melanoma.
- Other names
- plasmacytoid blood dendritic cell vaccineautologous pDC vaccinepDC vaccine
02
Targets
TYR (Tyrosinase)PMEL (Melanocyte Protein PMEL)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on plasmacytoid dendritic cell vaccine (Radboud University Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plasmacytoid dendritic cell vaccine (Radboud University Medical Center).